Infections in patients with lymphoproliferative diseases treated with targeted agents: SEIFEM multicentric retrospective study

Luca Laurenti, Livio Pagano, Maria Chiara Tisi, Stefano Maria Picardi, Gessica Marchesini, Gianpaolo Nadali, Davide Facchinelli, Anna Candoni, Chiara Cattaneo, Rosa Fanci, Francesca Farina, Federica Lessi, Andrea Visentin, Francesco Marchesi, Lucia Prezioso, Angelica Spolzino, Fabio Trastulli, Luisa Verga, Michelina Dargenio, Alessandro Busca

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

We describe the opportunistic infections occurring in 362 patients with lymphoproliferative disorders treated with ibrutinib and idelalisib in clinical practice. Overall, 108 of 362 patients (29·8%) developed infections, for a total of 152 events. Clinically defined infections (CDI) were 49·3% (75/152) and microbiologically defined infections (MDI) were 50·7% (77/152). Among 250 patients treated with ibrutinib, 28·8% (72/250) experienced one or more infections, for a total of 104 episodes. MDI were 49% (51/104). Bacterial infections were 66·7% (34/51), viral 19·6% (10/51) and invasive fungal diseases (IFD) 13·7% (7/51). Among the 112 patients treated with idelalisib, 32·1% (36/112) experienced one or more infections, for a total of 48 episodes. MDI were 54·2% (26/48). Bacterial infections were 34·6% (9/26), viral 61·5% (16/26) and IFD 3·8% (1/26). With ibrutinib, the rate of bacterial infections was significantly higher compared to idelalisib (66·7% vs. 34·6%; P = 0·007), while viral infections were most frequent in idelalisib (61·5% vs. 19·6%; P < 0·001). Although a higher rate of IFD was observed in patients treated with ibrutinib, the difference was not statistically significant (13·7% vs. 3·8% respectively; P = 0·18). Bacteria are the most frequent infections with ibrutinib, while viruses are most frequently involved with idelalisib.
Lingua originaleEnglish
pagine (da-a)316-324
Numero di pagine9
RivistaBritish Journal of Haematology
Volume193
DOI
Stato di pubblicazionePubblicato - 2021

Keywords

  • infections
  • lymphoproliferative diseases
  • targeted therapy

Fingerprint

Entra nei temi di ricerca di 'Infections in patients with lymphoproliferative diseases treated with targeted agents: SEIFEM multicentric retrospective study'. Insieme formano una fingerprint unica.

Cita questo